Finding the Overtime Sweet Spot in Manufacturing

 

Is overtime a good thing or a bad thing for a workforce and their employer? In this episode of the AEC Podcast, host Shelby Skrhak sat down with two experts — Frank Pereira and Ken Litke — to better understand the ins and outs of overtime and discover its elusive sweet spot.

“Every plant has a different DNA for overtime, where some places despise it, and some places love it,” Litke said.

Litke is a retired supply chain and manufacturing VP who has lead operations for Diageo, Land O’Lakes, Miller Coors, and Pillsbury and has turned to Coleman Consulting for help with overtime issues. Pereira is a US Naval Academy Grad, Gulf War veteran, and UC Berkeley MBA who is managing partner of Coleman Consulting Group. He’s worked with numerous Global 1000 companies to help them solve scheduling and productivity issues.

 Frank Pereira saysPereira said overusing overtime can be a vicious cycle where employees come to rely on extra overtime income as almost an “addiction” but risk burning out employees because of long hours and unpredictable schedules.

But when used correctly, overtime is essential to a productive, optimally-functioning shift. “Overtime is your best way to match your workforce to your workload,” Pereira said.

The key is using data to discover where the optimal balance is, they both said. On this episode, Pereira and Litke discussed how they found the overtime “sweet spot” at MillerCoors, the importance of ascertaining an individual’s tolerance for overtime, and dispel the notion that no overtime is good for business.

For the latest news, videos, and podcasts in the AEC Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More